Gastric GIST disease is the acronym for Gastrointestinal Mesenchymal Stromal Tumor. Gastrointestinal mesenchymal stromal tumors are the most common tumors of mesenchymal origin, with a relatively low incidence of 1-3% of GI tumors, of which 60-70% occur within the stomach and the rest in extragastric organs. The tumors originate from undirected differentiated mesenchymal cells of the gastrointestinal tract and are biologically characterized by mutations in the gene for C-kit, which lead to sustained activation of tyrosine kinase and stimulate sustained proliferation of tumor cells. Gastrointestinal mesenchymal tumors have no special clinical manifestations in the early stage, when the tumor increases in size there can be intra-tumor hemorrhage, ulceration and bleeding on the tumor surface, the most commonly used clinical examination means is gastroscopy. The most common clinical examination is gastroscopy. Surgery is the first choice for treatment, and the principle of surgical treatment should be thorough and complete resection, and ensure that there is no rupture of the tumor during the operation. According to the postoperative pathology, whether oral imatinib mesylate is needed for adjuvant therapy.